About CBT New Target Identification Corporate Information Latest News
 
Home How to find us Careers  
 



Board of directors




Management team



CBT Management Team

Robert Brooksbank M.A. Ph.D. - Head of Target Identifcation & Informatics
Robert is a founder of CBT. He has a background in bioinformatics, genomics and structural biology, at CBT he is responsible for target identification, IT, bioinformatics and cheminformatics. Previously he set up and led the bioinformatics group at Parke-Davis/Pfizer where he was involved in the identification and patenting of numerous new therapeutic targets.

Sandee Collins B.A. - Business Administrator
Sandee is a founder of CBT where she runs the business and administrative functions. She has a business degree and many years experience of Pharmaceutical industry administration gained whilst at Parke-Davis/Pfizer.

Mike Higginbottom B.Sc. - Head of Chemistry
Mike is a founder of CBT. Mike has many years experience in medicinal chemistry and in particular in the discovery of peptide mimetics and antagonists. He previously spent 16 years at Parke-Davis/Pfizer working on a range of different pain drug discovery programmes.

Yann Maneuf B.Sc. Ph.D. - Head of Biology
Yann is a founder of CBT. He is an expert in neuropharmacology and neurochemistry and runs the Pharmacology group at CBT. Previously he worked on the gabapentin and pregabalin programme at Parke-Davis/Pfizer.

Martyn Pritchard B.Sc. Ph.D. - Director of R&D
Martyn is a founder of CBT where he was initially Director of Chemistry. He has many years experience in medicinal chemistry and was formerly Associate Director of Chemistry, Parke-Davis/Pfizer, where three of his CNS drug discovery programmes entered clinical studies.

Peter Richardson M.A. Ph.D. - Managing Director
Peter is a founder of CBT where he was initially Chief Scientific Officer. He is also a senior lecturer in the Department of Pharmacology at the University of Cambridge. He invented novel technology for the amplification of mRNA from single cells and pioneered the use of Adenosine A2a antagonists for the treatment of Parkinson’s Disease. Peter was previously a consultant to Parke-Davis/Pfizer and Kyowa Hakko Kogyo Co.

Board of directors